In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMarin raises $67.5mm by selling priority review voucher to Sanofi/Regeneron

Executive Summary

Rare disease company BioMarin Pharmaceutical Inc.’s Irish subsidiary BioMarin GALNS Ltd. raised $67.5mm in cash by selling its priority review voucher (PRV) to Sanofi and Regeneron Pharmaceuticals Inc. (via Regeneron Ireland), which equally split the cost.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Priority Review Voucher (PRV) Sale

Related Companies